Format

Send to

Choose Destination
Curr Hematol Malig Rep. 2014 Sep;9(3):284-93. doi: 10.1007/s11899-014-0220-7.

Relapsed Hodgkin lymphoma: management strategies.

Author information

1
Department of Medicine, New York University School of Medicine, NYU Cancer Institute, 240 East 38th Street, 19th Floor, New York, NY, 10016, USA.

Abstract

Although Hodgkin lymphoma (HL) is largely curable with first-line therapy, approximately one-third of patients will not have a complete response to frontline treatment or will subsequently relapse. Only 50% of these patients will be effectively salvaged with conventional therapies. The prognosis is particularly poor for those patients with chemotherapy refractory disease, who are unable to obtain even transient disease control, and for patients who relapse following high dose chemotherapy and autologous stem cell transplant. In this review, we summarize the most recent updates on the management of patients with relapsed HL, the role of novel therapies such as brentuximab vedotin, and an overview of promising new agents currently under investigation. We also discuss the role of consolidation strategies such as high-dose chemotherapy and autologous stem cell transplant, and reduced-intensity allogeneic hematopoietic stem cell transplant, and the need for new strategies in the elderly patient population.

PMID:
24942298
PMCID:
PMC4909353
DOI:
10.1007/s11899-014-0220-7
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center